Table 4.
Ongoing and pending unpublished mesenchymal lineage trials.
| ClinicalTrials.gov Identifier | Study type | Cell type | Planned enrollment | Timing of delivery | Delivery route | Status |
|---|---|---|---|---|---|---|
| NCT01678534 “AMASCIS-01” Spain | Phase I/II Randomized Double-blinded | Allogeneic cultured single donor Adipose-derived MSCs | 40 | <14 days | IV | Completed—no results to date |
| NCT01716481 “STARTING-2” South Korea | Phase III Randomized Open-label | Autologous BM-derived MSCs, expanded in serum | 60 | <90 days | IV | Recruiting/ unknown |
| NCT00875654 “ISIS” France | Phase II Randomized Open-label | Autologous BM-derived MSCs | 31 | <6 weeks | IV | Completed, no results to date |
| NCT02448641 “ACTIsSIMA” USA | Phase II Randomized Double-blinded | BMMNC SB623 (cultured single donor modified BM-derived MSCs) | 156 | 6 months–7.5 years | IC | Completed, no results to date |
| NCT03570450 “RESSTORE-1” European Union | Phase I Randomized Open-label | Allogeneic adipose-derived mesenchymal stem cells | 15 | <1 week | IV | Recruiting |
| NCT02813512 Taiwan | Phase I Non-Randomized Open-label | Autologous ADSCs | 6 | >6 months | IC | Completed 2018 |
| NCT03356821 ”PASSIoN” Netherlands **Perinatal/neonatal stroke** | Phase I/II Non-Randomized Open-label | One dose of 50 × 106 Allogeneic BM-MSCs | 10 | <1 week | Nasal | Not yet recruiting |
| NCT03545607 “MASTERS-2” USA | Phase III Randomized Double-blinded | 1.2 × 106 MultiStem (Allogeneic BM multipotent progenitors) | 300 | 18–36 h | IV | Recruiting (see Hess et al., 2017 for MASTERS) |
| NCT02378974 S Korea | Phase I/II Randomized Double-blinded | Human Umbilical cord-derived Mesenchymal Stem Cells (“Cordstem-ST”) | 19 | <7 days | IV | Completed, results not yet published |
| NCT04063215 USA **chronic brain injury** | Phase I/II Non-Randomized Open-label | Autologous adipose-derived Mesenchymal Stem Cells (HOPE biosciences) | 24 | >6 months | IV | Recruiting |